In short
Clinical trials are studying Romosozumab in different patient groups, including children and adolescents with osteogenesis imperfecta and women with osteoporosis. These studies look at safety, fracture outcomes, bone density, and, in one trial, coronary atherosclerotic damage. The goal is to learn how Romosozumab performs in these specific research settings.
Key points
- Clinical trials investigating Romosozumab are looking at different patient groups, including children and adolescents with osteogenesis imperfecta and women with osteoporosis. The studies include Phase 3 research and one Phase IV study. Researchers are comparing Romosozumab with bisphosphonates and denosumab in some trials. Main outcomes include fractures, bone mineral density, adverse events, and coronary CT score. One trial also follows children and adolescents for safety after earlier treatment. Overall, the trials focus on both bone health and, in one study, heart artery damage in women with postmenopausal osteoporosis.
Clinical trial overview
The trial data show four interventional studies of Romosozumab in different patient groups. The studies are authorised and include Phase 3 research, one low-intervention study, and one Phase IV study. They focus on bone disease, fracture prevention, safety, and one heart-related imaging outcome in women with postmenopausal osteoporosis.
Studies in osteogenesis imperfecta
Two studies are in children, adolescents, and other participants with osteogenesis imperfecta, a condition where bones break more easily than normal. One Phase 3 study compares Romosozumab with bisphosphonates over 12 months and includes 122 participants. Its main goal is to measure the number of clinical fractures, the number of any fractures, and the change in lumbar spine bone mineral density measured by DXA, which is a scan used to check bone density.
The second osteogenesis imperfecta study is a pediatric safety follow-up study with 71 participants. It follows children and adolescents who already completed an earlier study of Romosozumab, whether they received the full planned treatment or stopped early. The main outcome is adverse events, meaning any unwanted medical problems seen during follow-up.
Studies in osteoporosis
The OPTIMIST study looks at Romosozumab in people with osteoporosis, a condition that makes bones weak and more likely to break. This study includes 270 participants and is designed to identify the best way to use Romosozumab by testing three treatment strategies. The primary outcome is the change in total hip bone mineral density after 24 months, which helps show whether bone strength improves over time.
This study compares Romosozumab with Aclasta, which is listed in the trial data as a comparison treatment. The study is described as low-intervention, meaning it uses treatment in a way that is close to usual care with limited extra research procedures.
Study of coronary atherosclerotic damage
The ATRIO study is a Phase 3 trial in women with postmenopausal osteoporosis and coronary atherosclerotic status, meaning the condition of plaque-related damage in the heart arteries. It includes 60 participants and compares Romosozumab with denosumab. The main outcome is the change in a coronary CT score adapted to the CCTA-Leaman method after 12 months of therapy.
This study is important because it does not only look at bone health, but also at a heart-artery imaging measure in a group of women already being treated for postmenopausal osteoporosis. The trial summary says the goal is to study the impact of Romosozumab, given according to standard care, on progression of coronary atherosclerotic damage compared with denosumab.
Main outcomes being measured
The trials measure different outcomes depending on the condition being studied. In the osteogenesis imperfecta study, researchers measure clinical fractures, any fractures, and lumbar spine bone mineral density Z-score at 12 months. In the pediatric follow-up study, the main focus is safety through adverse events.
In the OPTIMIST study, the main outcome is total hip bone mineral density at 24 months. In the ATRIO study, the main outcome is the coronary CT score after 12 months, which is used to track coronary artery damage. These outcomes help researchers judge whether the treatment strategies are effective and safe in each target group.
Who can participate
People in these trials are selected based on the condition being studied and the age group of the trial. The listed studies include children and adolescents with osteogenesis imperfecta, participants with osteoporosis, and women with postmenopausal osteoporosis.
Because these are clinical trials, each study has its own entry rules and treatment plan. The trial data show that Romosozumab is being studied in both bone-focused research and one study that also examines a heart-related imaging outcome.